Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment

Conditions:   Tuberculosis;   Tuberculosis, Pulmonary;   Bacterial Infections Respiratory;   Lung Diseases;   Mycobacterium Infections Intervention:   Drug: 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043 Sponsors:   Michael Hoelscher;   Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institut Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials